期刊文献+

骨质疏松治疗的研究进展 被引量:6

Latest Progress in the Therapy of Osteopporosis
下载PDF
导出
摘要 骨质疏松(osteoporosis,OP)是以骨脆性增加及骨折危险性升高为特征的全身骨量和骨组织形态改变的老年性疾病,尤其多见于绝经后女性.随着人口老龄化、人类寿命延长,该病已成为影响人类健康的第四类疾病,它的常见并发症:髋骨骨折在亚洲的发病人数将在未来50年内占全世界总发病人数的一半[1].因此,该病已越来越受到临床医生的重视.本文就临床上最多见、研究最多的成年型OP(包括绝经后OP和老年型OP)的治疗进展进行综述.
作者 熊茜
出处 《同济大学学报(医学版)》 CAS 2002年第6期522-525,共4页 Journal of Tongji University(Medical Science)
  • 相关文献

参考文献14

  • 1[1]Kung AW,Yeung SS,Chu LW.The efficacy and tolerability of alendronate in postmenopausal osteoporotic chinese women:a randomized placebo-controlled study[J].Calcif Tissue Int,2000,67(2):286-290.
  • 2[2]Arai H,Miyamoto KI,Yoshida M,et al.The polymorphism in the candal-related homeodomain protein Cdx-2 binding element in the human witamin D receptor gene[J].J Bone Miner Res,2001,16(9):1256-1264.
  • 3[3]Li YC,Bolt MJ,Cao LP,et al.Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism[J].Am J Physiol Endocrinol Metab,2001,281(suppl):558-564.
  • 4[4]Kadiyala S,Nagaba S,Takeuchi K,et al.Metabolites and analogs of lalpha,25*.dihydroxyvitaminD(3):evaluation of actions in bone[J].Steroids,2001,66(2):347-355.
  • 5[5]Reginster J,Minne HW,Sorensen OH,et al.Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.Vertebral efficacy with risedronate therapy (VERT) study group[J].Osteoporos Int,2000,11(1):83-91.
  • 6[6]Paul W,Phuong N,Cathleen V,et al.The estrogen receptor enhances AP*.1 activity by two distinct mechanisms with different requirement for receptor transativation functions[J].Mol Endocrinol,1999,139(10):1672-1685.
  • 7[7]Mitlak BH,Cohen FJ.Selective estrogen receptor modulators:A look ahead[J].Drugs,1999,57(4):653-663.
  • 8[8]Hua ZK,Hong QD.Lasofoxifen (CP*.336 156) a selective estrogen receptor modulator,prevents bone loss induced by aging and orchidectomy in the adult rat[J].Endocrinology,2000,141(9):1338-1344.
  • 9[9]Evdokiou A,Raggatt LJ,Sakai T,et al.Identification of a novel calcitonin-response element in the promoter of the human P21 WAFI/CIP1 gene[J].J Mol Endocrinol,2000,25(1):195-206.
  • 10[10]Gujer R,Aldecoa A,Buhlmann N,et al.Mutations of the asparagines (117) residue of a receptor activity-modifying protein 1*.dependent calcitonin gene-related peptide receptor result in selective loss of function[J].Biochemistry,2001,40(12):5392-5398.

同被引文献46

引证文献6

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部